<DOC>
	<DOCNO>NCT00723411</DOCNO>
	<brief_summary>The purpose study determine whether Diamyd ( rhGAD65 formulate alum ) effective preserve body 's insulin produce capacity patient recently diagnose type 1 diabetes .</brief_summary>
	<brief_title>A Phase III Study Investigate Impact Diamyd Patients Newly Diagnosed With Type 1 Diabetes ( EU )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Main Male female patient 10 20 year age Insulin dependent type 1 diabetes mellitus diagnose within previous 3 month time screen Fasting Cpeptide level time screen 0.1 nmol/L Elevated GAD65 antibody ( GADA ) time screen Main Treatment immunosuppressant antidiabetic medication insulin A history certain disease condition ( e.g . anemia , HIV , hepatitis , epilepsy , head trauma , neurological disease cerebrovascular accident , alcohol drug abuse etc ) Treatment vaccine within 1 month prior plan first Diamyd dose plan treatment vaccine 2 month last injection Diamyd , exclude influenza vaccine Participation clinical trial new chemical entity within previous 3 month Pregnancy plan pregnancy within 1 year last Diamyd dose Presence associate serious disease condition opinion investigator make patient noneligible study</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Juvenile Diabetes</keyword>
	<keyword>Diabetes type 1</keyword>
	<keyword>Autoimmune Diabetes</keyword>
	<keyword>Insulin dependent Diabetes</keyword>
	<keyword>Type 1 diabetes</keyword>
	<keyword>Type 1 diabetes mellitus</keyword>
	<keyword>Diamyd</keyword>
	<keyword>rhGAD65</keyword>
	<keyword>GAD</keyword>
	<keyword>GAD-alum</keyword>
</DOC>